ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0496

Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis

Valeria Gonzalez-Gonzalez1, Iris Colunga2, Dionicio A. Galarza-Delgado2, José Ramón Azpiri-López2, Rosa Arvizu-Rivera3, Jesus Alberto Cardenas-De la Garza4, Victor Beltran5 and Angel Arias Peralta6, 1Universidad Autónoma de Nuevo León, Monterrey, Mexico, 2Hospital Universitario UANL, Monterrey, Mexico, 3Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, 4Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, 5Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, 6Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico

Meeting: ACR Convergence 2023

Keywords: Cardiovascular, Measurement Instrument, Psoriatic arthritis, Spondyloarthropathies, Subclinical Cardiovascular Disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0483–0509) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: PsA

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The atherogenic index of plasma (AIP) is a predictor of atherosclerosis and coronary heart disease. In patients with systemic lupus erythematosus and rheumatoid arthritis, AIP is correlated with increased cardiovascular risk measured by Framingham’s risk score. The correlation between AIP and calculated cardiovascular risk has not been studied in PsA-patients. To evaluate the correlation between AIP and six cardiovascular risk scores in patients with PsA.

Methods: Cross-sectional study that included PsA-patients aged 40 to 75 years who fulfilled the 2006 Classification Criteria for PsA. Patients with previous cardiovascular disease were excluded. AIP was defined by log (TG/HDL-C) mg/dL, and levels ≥0.21 were considered as high AIP. Cardiovascular disease risk was evaluated using 6 algorithms: ACC/AHA 2013, FRS-Lipids, FRS-BMI, RRS, QRISK3, and SCORE2. The Kolmogorov-Smirnov test was performed to evaluate the distribution of variables. The correlation between the AIP and cardiovascular risk algorithms was assessed by Spearman’s correlation coefficient. A value of p≤0.05 was considered statistically significant.

Results: A total of 94 patients with PsA were included, mostly women (n=52, 55.3%), the mean age was 53 ± 11.2, the disease duration of PsA was 5.0 (2.0-10.0) years, and the median AIP of all patients included was 0.49 (0.35-0.67). The median of each algorithm was: FRS-BMI 15.0 (6.7-27.8), FRS-Lipids 7.4 (3.0-16.4), SCORE 1.0 (1.0-3.0), QRISK3 5.6 (2.4-12.5), RRS 3 (2.0-7.5) and ACC/AHA 2013 5.3 (2.1-14.5). The most prevalent cardiovascular risk factor was dyslipidemia (n= 41, 43.6%). All cardiovascular risk algorithms presented a high positive correlation between AIP levels and cardiovascular risk. The calculator with the highest correlation was ACC/AHA 2013 (rs=0.641, p=0.000). (Table 1 and Figure 1).

Conclusion: In patients with PsA, higher values of AIP are associated with increased cardiovascular risk irrespective of the algorithm used. High AIP values could identify patients who would benefit from a non-invasive evaluation for subclinical atherosclerosis.

Supporting image 1

Table 1. Correlations between cardiovascular risk algorithms and AIP.

Supporting image 2

Figure 1. Scatterplots of the correlations between cardiovascular risk algorithms and AIP.


Disclosures: V. Gonzalez-Gonzalez: None; I. Colunga: None; D. Galarza-Delgado: None; J. Azpiri-López: None; R. Arvizu-Rivera: None; J. Cardenas-De la Garza: None; V. Beltran: None; A. Arias Peralta: None.

To cite this abstract in AMA style:

Gonzalez-Gonzalez V, Colunga I, Galarza-Delgado D, Azpiri-López J, Arvizu-Rivera R, Cardenas-De la Garza J, Beltran V, Arias Peralta A. Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/higher-values-of-atherogenic-index-of-plasma-are-correlated-with-increased-cardiovascular-risk-in-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/higher-values-of-atherogenic-index-of-plasma-are-correlated-with-increased-cardiovascular-risk-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology